


Mutational Signature


Percent of SNVs
attributed to signature



Treatment


carboplatin
paclitaxel
iposomal doxorubicin
gemcitabine
cyclophosphamide
topotecan
cisplatin
olaparib
bevacizumab
docetaxel
nab-paclitaxel/
farletuzumab/placebo
etoposide

Cisplatin *G. gallus*
Cyclophosphamide *G. gallus*
Etoposide *G. gallus*
Cisplatin *C. Elegans*
(1) Age
(2) BRCA
(3) BRCA
(4) MMR
(5) MMR
(6) MMR
(7) MMR
(8) AID
(9) AID
(10) POLE
(11) POLE
(12) AID
(13) AID
(14) AID
(15) AID
(16) AID
(17) AID
(18) AID
(19) AID
(20) AID
(21) AID
(22) AID
(23) AID
(24) AID
(25) MMR
(26) MMR
(27) MMR
(28) MMR
(29) Tobacco
(30) Signature 30



AOCS-034-1-0
AOCS-064-1-6
AOCS-065-1-9
AOCS-086-1-5
AOCS-088-1-0
AOCS-091-1-3
AOCS-092-1-6
AOCS-093-1-9
AOCS-093-8-4
AOCS-094-1-1
AOCS-095-1-4
AOCS-137-1-X
AOCS-139-1-5

Pre-treatment



AOCS-034-3-8
AOCS-064-3-3
AOCS-065-3-6
AOCS-086-3-2
AOCS-088-3-8
AOCS-091-3-0
AOCS-092-3-3
AOCS-093-3-6
AOCS-094-6-X
AOCS-095-3-1
AOCS-137-3-7
AOCS-139-12-5
AOCS-139-19-0
AOCS-139-6-3

Post-treatment unique